Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Intervention Indication Therapeutic Area Year Actions
Tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis homozygous for F508del mutation in patients aged 6 to 11 years Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor) Cystic fibrosis Genetic Disorders , Respiratory System 2019 View  |  Download
Ticagrelor in addition to acetylsalicylic acid for prevention of stroke in patients with acute ischaemic stroke or transient ischaemic attack Ticagrelor (Brilique; AZD6140) Stroke Cardiovascular System 2019 View  |  Download
Tisotumab vedotin for recurrent or metastatic cervical cancer Tisotumab vedotin (HuMax-TF-ADC) Cervical cancer Female Reproductive Cancer 2019 View  |  Download
Tofacitinib for polyarticular juvenile idiopathic arthritis Tofacitinib citrate (Xeljanz; CP-690550) Juvenile idiopathic arthritis Rheumatology 2019 View  |  Download
Tralokinumab for atopic dermatitis Tralokinumab (CAT-354; LP 0162) Atopic dermatitis Dermatology 2019 View  |  Download
Trastuzumab deruxtecan for HER2-positive metastatic or unresectable breast cancer Trastuzumab deruxtecan (DS-8201a; Enhertu) Breast cancer Breast Cancer 2019 View  |  Download
Trastuzumab emtansine in combination with pertuzumab for HER2-positive early breast cancer - adjuvant therapy Pertuzumab (Perjeta; R-1273) , Trastuzumab Emtansine (Kadcyla; T-DM1; PRO132365) Breast cancer Breast Cancer 2019 View  |  Download
Treosulfan in combination with fludarabine for paediatric non-malignant disease before allogeneic stem cell transplant Fludarabine (fludarabine phosphate) , Treosulfan (Ovastat) Non-malignant diseases Endocrine Nutritional and Metabolic Disorders , Haematology , Immunology 2019 View  |  Download
Upadacitinib for active psoriatic arthritis with inadequate response to biological or non-biological DMARDs Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Psoriatic arthritis Dermatology , Rheumatology 2019 View  |  Download
Upadacitinib for atopic dermatitis Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Atopic dermatitis Dermatology 2019 View  |  Download
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications